Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children

Pediatric Infectious Disease Journal

Volumn 22, Issue 10, 2003, Pages 863-868

  Snchez Granados, José Manuel ^a   Ramos Amador, José Toms ^a   De Miguel, Sira Fernndez ^a   Gonzlez Tomé, Mara Isabel ^a   Conejo, Pablo Rojo ^a   Vivas, Paloma Ferrando ^a   Polln, Julin Clemente ^a   Contreras, Jeses Ruiz ^a   Espert, Angel Nogales ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Acquired immunodeficiency syndrome; Children; Highly active antiretroviral therapy; Human immunodeficiency virus; Infections; Lymphoid interstitial pneumonia; Organ specific complications; Survival

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTERSTITIAL PNEUMONIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SPAIN; SURVIVAL; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAUSE OF DEATH; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HOSPITALIZATION; HUMANS; INFANT; MALE; MULTIVARIATE ANALYSIS; ODDS RATIO; PROBABILITY; REFERENCE VALUES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SPAIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0142089125     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/01.inf.0000091282.70253.5f     Document Type: Article

References (18)

1. UNAIDS/WHO Working Group on Global HIV/AIDS and STD Surveillance. Report on the Global HIV/AIDS 2002. Available at http://www.unaids.org.
2. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337: 725-33.
3. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
4. Melvin AJ, Mohan KM, Arcuino LA, Edelstein RE, Frenkel LM. Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors. Pediatr Infect Dis J 1997; 16: 968-74.
5. Nachman SA, Stanley K, Yogev R, et al. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial: Pediatric AIDS Clinical Trials Group 338 Study Team. JAMA 2000; 283: 492-8.
6. Mueller BU, Sleasman J, Nelson RP Jr, et al. A Phase I/II study of the protease inhibitor indinavir in children with HIV infection. Pediatrics 1998; 102: 101-9.
7. Wiznia A, Stanley K, Krogstad P, et al. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: Week 24 results of a randomized controlled trial&OV0093;PACTG 377: Pediatric AIDS Clinical Trials Group 377 Study Team. AIDS Res Hum Retroviruses 2000; 16: 1113-21.
8. de Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection: Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA 2000; 284: 190-7.
9. Canani RB, Spagnuolo MI, Cirillo P, Guarino A. Decreased needs for hospital care and antibiotics in children with advanced HIV-1 disease after protease inhibitor-containing combination therapy. AIDS 1999; 13: 1005-6.
10. Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001; 345: 1522-8.
11. Gibb A, Duong T, Mc Gee L, Sharland M, Tookey P. Effects of ART on morbidity and mortality of UK and Irish HIV infected children [Abstract TuPeC4730]. In: XIV International AIDS Conference, Barcelona, July 7 to 12, 2002.
12. Saulsbury F. Resolution of organ-specific complications of human immunodeficiency virus infection in children with use of highly active antiretroviral therapy. Clin Infect Dis 2001; 32: 464-8.
13. Indacochea FJ, Scott GB. HIV infection and the acquired immunodeficiency syndrome in children. Curr Probl Pediatr 1992; 22: 166-204.
14. The European Collaborative Study. Fluctuations in symptoms in human immunodeficiency virus-infected children: the first 10 years of life. Pediatrics 2001; 108: 116-22.
15. Centers for Disease Control and Prevention. 1994. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994; 43 (RR-12):1-10.
16. Blanche S, Newell ML, Mayaux MJ, et al. Morbidity and mortality in European children vertically infected by HIV-1: The French Pediatric HIV Infection Study Group and European Collaborative Study. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14: 442-50.
17. Barnhart HX, Caldwell MB, Thomas P, et al. Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project. Pediatrics 1996; 97: 710-16.
18. Sharland M, di Zub GC, Ramos JT, Blanche S, Gibb DM. PENTA guidelines for the use of antiretroviral therapy in pediatric HIV infection: Pediatric European Network for Treatment of AIDS. HIV Med 2002; 3: 215-26.